ANL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Adlai Nortye enters a clinical collaboration with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximabOct 15, 2026
- Adlai Nortye submitted a clinical trial notification and received HREC approval for the Phase 1 trial of AN4035 in AustraliaAug 3, 2026
- Adlai Nortye dosed the first patient in the intermittent weekly dosing arm of the global Phase 1 trial of AN9025Jul 16, 2026
- Adlai Nortye enrolled the first patient in a global Phase 1 trial of the pan-RAS inhibitor AN9025 for solid tumors with RAS mutationsFeb 12, 2026
- Adlai Nortye licenses pan-RAS inhibitor AN9025 to ASK Pharm for Greater ChinaDec 29, 2025